SPARCL1 and metabolic dysfunction-associated steatohepatitis: Taken together, the experimental model of the current study hypothesized that (Figure 6) treatment of the NASH animals with rosavin for four weeks significantly downregulated the expression of hepatic lncRNA lnc-SPARCL1-1:2, resulting in the downregulation of hepatic miRNA-6881-5P miRNA concomitant with a decrease in the levels of hepatic cell death-related players including (i) HSPD1 (Oxidative stress response), (ii) TNF-a and IL-6 (Inflammatory response), (iii) MMP14 and ITGB1 (Cell detachment and anoikis cell death), and (iv) caspase-3 (Apoptosis).